Opko Pharmaceuticals, LLC
Records under this name other than the patents Opko Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 10 of 10 · Back to Opko Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,872,118 | Sirna and Methods of Manufacture Formerly held In force · High confidence | In force | High confidence | |
| US 11,215,618 | Articles and Methods Directed to Personalized Therapy of Cancer Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,804,168 | Biomarker Discovery in Complex Biological Fluid Using Bead or Particle Based Libraries and Diagnostic Kits and Therapeutics Lapsed on the fee record Ended Oct 31, 2025 · Medium confidence | Lapsed on the fee record | Ended Oct 31, 2025 | Medium confidence |
| US 10,829,509 | Pure heptasulfated disaccharides having improved oral bioavailability Lapsed on the fee record Ended Nov 10, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 10, 2024 | From the USPTO record |
| US 8,227,444 | Compositions and Methods for Inhibition of VEGF Formerly held Lapsed on the fee record Ended Jul 24, 2024 · High confidence | Lapsed on the fee record | Ended Jul 24, 2024 | High confidence |
| US 8,202,845 | Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification Formerly held Term ended Ended no later than Apr 16, 2023 · Medium confidence | Term ended | Ended no later than Apr 16, 2023 | Medium confidence |
| US 8,946,180 | Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification Formerly held Lapsed on the fee record Ended Feb 3, 2023 · High confidence | Lapsed on the fee record | Ended Feb 3, 2023 | High confidence |
| US 8,603,756 | Antigen surrogates in autoimmune disease Lapsed on the fee record Ended Dec 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 10, 2021 | From the USPTO record |
| US 8,470,792 | Compositions and Methods for Selective Inhibition of VEGF Formerly held Lapsed on the fee record Ended Jun 25, 2021 · High confidence | Lapsed on the fee record | Ended Jun 25, 2021 | High confidence |
| US 9,458,199 | Antigen surrogates in autoimmune disease Lapsed on the fee record Ended Oct 4, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 4, 2020 | From the USPTO record |